A biotech company is suing to block Merck & Co. from launching an easier-to-use version of its blockbuster cancer treatment ...

Halozyme is not holding back against Merck & Co. in the companies' injectable Keytruda patent dispute, having now escalated a ...

Drugmaker Merck reports quarterly results Thursday morning as fears grow over the expiration of the patent on its top-selling ...

Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data ...

Merck’s first-quarter net income increased as sales of its Keytruda cancer drug rose, but the Big Pharma company cut its 2025 ...

The company’s stock fell as much as 2.8% after markets opened in New York Thursday. For the first quarter, Merck’s results ...

Keytrda “still reigns” after the interim analysis for Akeso and Summit Therapeutics (SMMT)’ PD-1/VEGF “muddies the outlook” for a potential ivonescimab survival benefit in non-small cell lung cancer.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), a biotechnology company that pioneered the use of human hyaluronidase ...

With potential tariffs and other drug pricing policies on the horizon, the industry is navigating uncertain waters. | The ...

Presentations at this year’s American Association for Cancer Research meeting could have a broad impact on the treatment ...

MRK posts better-than-expected first-quarter results but trims its 2025 EPS outlook due to anticipated one-time charges.

Merck on Thursday said its first-quarter adjusted profit rose 7% as lower costs helped offset a 2% decline in sales, ...